Vial develops immunology and metabolic medicines, combining AI-guided molecule design, experimental validation, and its clinical-trial platform to advance investigational therapies.
Products & media
IL-13 x TSLP
Investigational bispecific antibody program targeting IL-13 and TSLP for inflammatory diseases; the official pipeline lists Phase 1 development.
INHBE siRNA
Investigational RNA interference program targeting INHBE for obesity; the official pipeline lists Phase 1 development.
Team
Founders
1 person
Jobs
See all jobs for Vial here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels
Series B
$67M